All In Biotech

Drug Trial Radar · NCT06925321

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.

An Interventional Phase 3, Open-label, Two-cohort Study to Investigate the Efficacy and Safety of Fosmanogepix in Adult Patients With Invasive Mold Infections Caused by Aspergillus Spp., Fusarium Spp., Lomentospora Prolificans, Mucorales Fungi, or Other Multidrug Resistant Molds

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 234 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

234

Planned (sponsor's estimate)

Start

Aug 26, 2025

Primary completion

Feb 2028

Study completion Feb 2028

Sponsor

Lead sponsor
Basilea PharmaceuticaIndustry
Sponsor type
Industry
Collaborators
Biomedical Advanced Research and Development Authority
First posted
Apr 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of fosmanogepix (administered IV or oral) for the treatment of adult patients with invasive mold infections. The study is looking for patients who have been diagnosed with invasive mold infections. The maximum study duration will be approximately 8 months, including a target study treatment duration of 84 days which can be extended up to 180 days and follow-up period. The patient will be assigned to one of two treatment cohorts: Cohort A (primary therapy): Patients will receive either the study drug or institutional standard of care antifungal treatment. Cohort B (salvage treatment; i.e. treatment given after patients did not respond to previous treatments or did not tolerate them): Patients will receive the study drug The primary aim is to compare the all cause mortality with a fixed threshold at Day 42.

Conditions

  • Invasive Mold Infections

Interventions

  • Fosmanogepix IV infusionDrug

    Fosmanogepix will be administered IV

  • Standard of care antifungal therapyDrug

    Standard of care antifungal therapy will be administered in accordance with their respective product labels and/or standard practice guidelines

  • Fosmanogepix oral tabletDrug

    Fosmanogepix will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Day 42 all-cause mortality rateTime frame: Day 42

Locations

90 sites in 15 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham School of Medicine, Department of Medicine

    Birmingham, Alabama · Recruiting

  • City of Hope

    Duarte, California · Recruiting

  • David Geffen School of Medicine at UCLA

    Los Angeles, California · Recruiting

  • UC Davis Medical Center

    Sacramento, California · Recruiting

  • Memorial Healthcare System

    Hollywood, Florida · Recruiting

  • Rush University Medical Center, Division of Infectious Diseases

    Chicago, Illinois · Recruiting

  • University of Kentucky Medical Center, Division of Infectious Diseases

    Lexington, Kentucky · Recruiting

  • Johns Hopkins Hospital

    Baltimore, Maryland · Recruiting

  • University of Michigan Health System (UMHS) - A. Alfred Taubman Health Care Center

    Ann Arbor, Michigan · Recruiting

  • Karmanos Cancer Institute - Detroit

    Detroit, Michigan · Terminated

  • University of Minnesota, M Health Fairview Medical Center

    Minneapolis, Minnesota · Recruiting

  • Washington University School of Medicine, Infectious Diseases Clinical Research Unit

    St Louis, Missouri · Recruiting

  • Weill Cornell Medical College - NewYork-Presbyterian Hospital

    New York, New York · Recruiting

  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina · Recruiting

  • Duke University Medical Center, Duke Infectious Diseases

    Durham, North Carolina · Recruiting

  • University of Pennsylvania School of Medicine

    Philadelphia, Pennsylvania · Recruiting

  • The University of Texas Health Science Center at Houston, Department of Internal Medicine

    Houston, Texas · Recruiting

  • UT MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • University of Texas Health Science Center at San Antonio

    San Antonio, Texas · Recruiting

  • Monash Medical Center Clayton

    Clayton, Australia · Recruiting

  • The Alfred Hospital

    Melbourne, Australia · Recruiting

  • Peter MacCallum Cancer Center

    Melbourne, Australia · Recruiting

  • Royal Melbourne Hospital

    Parkville, Australia · Recruiting

  • Westmead Hospital

    Westmead, Australia · Recruiting

  • Princess Alexandra Hospital

    Woolloongabba, Australia · Recruiting

  • Sir Charles Gairdner Hospital

    Nedlands, Western Australia, Australia · Recruiting

  • Kepler University Hospital GmbH, Department of Internal Medicine IV - Pulmonology

    Linz, Austria · Recruiting

  • Medical University Vienna, Department of Internal Medicine I, Clinical Department of Infections and Tropical Medicine

    Vienna, Austria · Recruiting

  • General Hospital Saint-Jan

    Bruges, Belgium · Recruiting

  • Charleroi Grand Hospital (GHDC) - Les Viviers Site

    Charleroi, Belgium · Recruiting

  • Jessa Hospital

    Hasselt, Belgium · Recruiting

  • University Hospitals Leuven, Campus Gasthuisberg, Department of Hematology

    Leuven, Belgium · Recruiting

  • UCL Mont-Godinne University Hospitals

    Yvoir, Belgium · Recruiting

  • Porto Alegre Clinical Hospital (HCPA)

    Porto Alegre, Brazil · Recruiting

  • Hospital A.C.Camargo ("Antonio Prudente" Foundation)

    São Paulo, Brazil · Suspended

  • "Santa Marcelina" Hospital

    São Paulo, Brazil · Recruiting

  • HC-UFPR

    Curitiba, Paraná, Brazil · Recruiting

  • Hospital Our Lady of Grace

    Curitiba, Paraná, Brazil · Recruiting

  • Paulista School of Medicine at Federal University of Sao Paulo, UNIFESP

    São Paulo, São Paulo, Brazil · Recruiting

Showing 40 of 90 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.